WMS 2022 poster: Ataluren preserves upper limb function in nmDMD patients from Study 041, a phase 3 placebo-controlled trial, and the STRIDE Registry
This poster, presented at WMS 2022, shows findings from a registry study investigating the effects of a mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on upper limb function
Read more about the baseline demographics of patients with nmDMD in both study populations
Discover the results obtained from analysis of the STRIDE Registry of real-world data, compared with those of Study 041, a phase 3, placebo-controlled trial
Discover upper limb function outcomes in both studies
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This poster was developed and funded by PTC Therapeutics for WMS 2022.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300003 | February 2023
Sign in or register to access exclusive content on this site